How to buy Redhill Biopharma stock (RDHL)

Redhill Biopharma is a drug manufacturers - specialty & generic business based in the US. Redhill Biopharma shares (RDHL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.55 – an increase of 0.77% over the previous week. Redhill Biopharma employs 53 staff and has a trailing 12-month revenue of around $3.7 million.

Our top picks for where to buy Redhill Biopharma stock

Buy Redhill Biopharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Redhill Biopharma stock price (NASDAQ: RDHL)

Use our graph to track the performance of RDHL stocks over time.

Redhill Biopharma shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$6.55
52-week range	$6.00 - $38.50
50-day moving average more info button	$7.63
200-day moving average more info button	$9.80
Wall St. target price	$19,000.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-302.63

Is it a good time to buy Redhill Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Redhill Biopharma price performance over time

Historical closes compared with the close of $6.35 from 2024-12-24

1 week (2024-12-19)	-1.85%
1 month (2024-11-27)	-20.23%
3 months (2024-09-26)	-31.87%
6 months (2024-06-26)	1,606.53%

1 year (2023-12-26)	326.17%
2 years (2022-12-23)	-95.99%
3 years (2021-12-23)	2640
5 years (2019-12-26)	6400

Redhill Biopharma financials

Revenue TTM	$3.7 million
Gross profit TTM	$45.3 million
Return on assets TTM	-44.88%
Return on equity TTM	-1708.61%
Profit margin	0%
Book value	$0.05
Market Capitalization more info button	$8.1 million

TTM: trailing 12 months

Redhill Biopharma share dividends

We're not expecting Redhill Biopharma to pay a dividend over the next 12 months.

Have Redhill Biopharma's shares ever split?

Redhill Biopharma's shares were split on a 1:25 basis on 19 August 2024 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Redhill Biopharma shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Redhill Biopharma shares which in turn could have impacted Redhill Biopharma's share price.

Redhill Biopharma share price volatility

Over the last 12 months, Redhill Biopharma's shares have ranged in value from as little as $6.0001 up to $38.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Redhill Biopharma's is 3.671. This would suggest that Redhill Biopharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Redhill Biopharma overview

RedHill Biopharma Ltd. , a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. .

Frequently asked questions

What percentage of Redhill Biopharma is owned by institutions?
Currently 5.904% of Redhill Biopharma shares are held by institutions. How many people work for Redhill Biopharma?
Latest data suggests 53 work at Redhill Biopharma. When does the fiscal year end for Redhill Biopharma?
Redhill Biopharma's fiscal year ends in December. Where is Redhill Biopharma based?
Redhill Biopharma's address is: 21 Ha?arba?a Street, Tel Aviv, Israel, 6473921 What is Redhill Biopharma's ISIN number?
Redhill Biopharma's international securities identification number is: US7574681034 What is Redhill Biopharma's CUSIP number?
Redhill Biopharma's Committee on Uniform Securities Identification Procedures number is: 757468103